Posted by Michael Wonder on 06 May 2021
European Commission approves Benlysta for adult patients with active lupus nephritis
5 May 2021 - First and only biologic approved for both systemic lupus erythematosus and lupus nephritis
GlaxoSmithKline today announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis in Europe, in addition to systemic lupus erythematosus.
The EU marketing authorisation follows the recent approval for the similar expanded lupus nephritis indication in the U.S.
